US Federal House Bill HB8716

US Federal 2025-2026 Regular Session

• Introduced: 5/7/26
• Refer: 5/7/26

Caption

Blood Pressure MATTERS Act

Summary

HB8716, the Blood Pressure MATTERS Act, would require coverage of self-measured blood pressure monitoring for pregnant and postpartum individuals across Medicaid, CHIP, private group and individual health plans, ERISA-covered employer plans, and certain tax code-regulated health coverage. The bill defines the covered benefit as a specified blood pressure measurement device that can be used at home without a health care provider, has FDA 510(k) clearance, and is listed on the American Medical Association’s validated device list. Coverage would apply during pregnancy and for the 12 months after pregnancy ends, with a limit of one device per individual every two years. The bill also bars cost sharing for the covered device and prohibits plans from conditioning coverage on a diagnosis of a hypertensive disorder. In Medicaid and CHIP, states would be required to include the benefit, with effective dates generally 120 days after enactment, though states needing legislation would get additional time to conform their plans. The bill amends the Social Security Act, the Public Health Service Act, ERISA, and the Internal Revenue Code to create parallel coverage rules across public programs and private insurance markets.

Impact

If enacted, the bill would add a new mandatory covered benefit for pregnant and postpartum individuals in Medicaid and CHIP and would impose a federal coverage mandate on most private health coverage, including employer-sponsored plans and individual market plans. It would also preempt or limit plan design choices by prohibiting cost sharing and by preventing insurers from requiring a hypertension diagnosis before covering the device. States would need to update Medicaid and CHIP plans, and some may need legislative action to comply. The bill would affect pregnant and postpartum enrollees, health insurers, employers sponsoring health plans, and state Medicaid/CHIP administrators.

Sentiment

The available context shows no committee debate or recorded votes, so there is no documented opposition or support in the provided materials. Based on the bill text, the measure appears to be framed as a maternal health and preventive care expansion intended to improve blood pressure monitoring during pregnancy and the postpartum period. The introduction by multiple House members suggests sponsorship interest, but the legislative history provided is limited to referral.

Contention

The main policy tensions likely concern the breadth of the mandate and the cost implications for Medicaid programs, CHIP, insurers, and employer plans, especially because the bill requires coverage without cost sharing and without a prior hypertension diagnosis. Another possible point of contention is federal preemption of state and plan-level benefit design, along with the requirement that states conform their Medicaid or CHIP plans, sometimes through additional state legislation. The bill also limits coverage to one validated device every two years, which may be seen as a cost-control measure but could still prompt questions about adequacy and implementation.